ArticlePloS one2012
Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Ventilator-associated pneumonia related to extended-spectrum beta-lactamase producing Enterobacterales during severe acute respiratory syndrome coronavirus 2 infection: risk factors and prognosis.Critical care (London, England) · 2024Article
- Observational
- Quantitative evaluation of extended-spectrum β-lactamase-producing Escherichia coli strains in the wastewater of a French teaching hospital and relation to patient strain.Antimicrobial resistance and infection control · 2016Article
- High prevalence of the animal-associated bla CTX-M-1 IncI1/ST3 plasmid in human Escherichia coli isolates.Antimicrobial agents and chemotherapy · 2015Article
- Urinary tract infections and antimicrobial sensitivity among diabetic patients at Khartoum, Sudan.Annals of clinical microbiology and antimicrobials · 2015Article
- A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.Antimicrobial agents and chemotherapy · 2014Review
- Escherichia coli ST131, an intriguing clonal group.Clinical microbiology reviews · 2014Review
- Replicon typing of plasmids carrying bla CTX-M-1 in Enterobacteriaceae of animal, environmental and human origin.Frontiers in microbiology · 2014Article
- Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries.Antimicrobial agents and chemotherapy · 2014Article
- Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: a multicentre case-case comparison study.Antimicrobial resistance and infection control · 2014Article
- Urinary tract infection in diabetes: epidemiologic considerations.Current infectious disease reports · 2014Article
- Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolates.PloS one · 2013Article
- Article
- Phylogenetic distribution of CTX-M- and non-extended-spectrum-β-lactamase-producing Escherichia coli isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes.Journal of clinical microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal dissemination of Escherichia coli producing CTX-M extended-spectrum β-lactamases (ESBL) is a public health concern. The aim of the study was to determine factors associated with CTX-M- producing E. coli infections among patients hospitalised in the Assistance Publique-Hôpitaux de Paris, the largest hospital system in France (23 000 beds), through a prospective case-control-control study. METHODS/PRINCIPAL
findingsFrom November 2008 to June 2009, 152 inpatients with a clinical sample positive for CTX-M-producing E. coli (cases), 152 inpatients with a clinical sample positive for non ESBL-producing E. coli on the day or within the three days following case detection (controls C1), and 152 inpatients with culture-negative clinical samples since the beginning of hospitalisation and until three days after case detection (controls C2) were included in ten hospitals of the Paris area. Factors studied were related to patient's origin, lifestyle and medical history as well as care during hospitalisation. Those independently associated with CTX-M-producing E. coli were determined. Three independent factors were common to the two case-control comparisons: birth outside of Europe (cases vs C1: OR(1) = 2.4; 95%CI = [1.3-4.5] and cases vs C2: OR(2) = 3.1; 95%CI = [1.4-7.0]), chronic infections (OR(1) = 2.9; 95%CI = [1.3-6.9] and OR(2) = 8.7; 95%CI = [2.0-39.7]), and antibiotic treatment between hospital admission and inclusion (OR(1) = 2.0; 95%CI = [1.0-3.8] and OR(2) = 3.3; 95%CI = [1.5-7.2]). Cases were also more likely to be (i) functionally dependent before hospitalisation than C2 (OR(2) = 7.0; 95%CI = [2.1-23.5]) and (ii) living in collective housing before hospitalisation than C2 (OR(2) = 15.2; 95%CI = [1.8-130.7]) when CTX-M-producing E. coli was present at admission.
conclusionFor the first time, patient's origin and lifestyle were demonstrated to be independently associated with isolation of CTX-M-producing E. coli, in addition to health care-related factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.